查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836889

蛋白质治疗市场按治疗方式、治疗领域、给药途径、剂型和最终用户划分－全球预测 2025-2032

Protein Therapeutics Market by Modality, Therapeutic Area, Route Of Administration, Dosage Form, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年蛋白质治疗市场将成长至 1,585.7 亿美元，复合年增长率为 8.13%。

主要市场统计数据
基准年2024年 848亿美元
预计2025年 917.9亿美元
预测年份：2032年 1585.7亿美元
复合年增长率（%） 8.13%

权威介绍将蛋白质疗法定义为一个融合领域，其中科学创新、供应弹性和商业策略将决定患者影响和产业发展轨迹

蛋白质疗法已从利基生物干预手段发展成为现代医学的核心支柱，透过提升特异性、有效性和个人化，在多个治疗领域推动患者照护。这项发展策略将科学创新与营运现实相结合，并协调研究、生产、临床开发和商业化过程中相关人员的期望，从而提供了对当代情况的全面洞察。此策略将酵素、融合蛋白、荷尔蒙、干扰素、单株抗体、重组蛋白和疫苗等细分领域视为相互关联的模式，构成一个复杂的发现和交付生态系统。

随着治疗模式的多样化，市场路径和组织面临的策略选择也随之多样化。蛋白质工程和製剂的创新正在降低免疫抗原性并提高稳定性，而给药方式的创新则正在扩大传统肠外给药以外的可行给药途径。同时，不断变化的付款人动态和监管审查正在改变临床开发和生命週期管理的计算方式，这强化了对综合证据生成策略的需求——该策略应侧重于转化影响、供应链弹性和商业性化准备，以使相关人员能够清晰、有目的地应对科学的复杂性和政策变化。

在以下章节中，读者将发现重点是可行的见解而不是抽象的趋势，目的是为领导者提供实用的基础，以使他们研发组合、製造投资和打入市场策略与当今塑造蛋白质疗法的科学和系统力量保持一致。

最新的技术趋势、监管演变和付款人期望的变化如何融合在一起从根本上重塑蛋白质治疗的发现、开发和商业策略。

由于技术突破、监管现代化以及相关人员期望的转变，蛋白质治疗领域正在发生重大变化。精准糖工程和Fc区优化等分子工程的进展延长了单株抗体和融合蛋白的功能寿命，并扩大了其在目标组织的分布。同时，新一代重组表现系统和无细胞生产平台正在降低生产差异性，缩短开发时间，并实现复杂生技药品更可重复的递送。

随着这些技术进步，临床模式正转向组合方案和生物标记主导的患者选择。同时，在罕见疾病领域，对遗传发病机制的深入了解正在加速标靶蛋白质替代疗法和酵素疗法的开发。同时，诸如鼻腔内给药和经皮给药等肠外给药方法正从概念验证阶段转向针对特定适应症的早期临床应用。

此外，法律规范正在适应蛋白质疗法的独特特性。开发组织正在完善有关生物相似性、互换性和真实世界证据接受度的指导，这为开发人员带来了机会，也带来了复杂性。加速途径和自适应测试设计方面的监管灵活性使得人们能够更快地获得突破性治疗方法，但也增加了核准后安全监测和生产控制的障碍。最后，付款人动态和价值驱动的合约正在重塑商业策略，促使申办方考虑风险分担模式，将证据生成与长期结果相结合，并将报销与已证实的临床效用挂钩。这些共同的力量正在重新定义组织如何优先考虑资产、建立伙伴关係以及投资从发现到交付的能力。

全面分析 2025 年美国计画加征关税对蛋白质治疗价值链产生的连锁业务、供应链和伙伴关係影响

分析2025年美国宣布的关税的累积影响及其对蛋白质疗法的影响，必须从多个营运和策略角度进行分析。影响原料、实验室耗材、设备和半成品的贸易措施将增加成本并使采购流程复杂化，尤其对于依赖专业投入和高品质试剂的生技药品製造商。实际上，关税可能会延长关键供应品的前置作业时间，给库存管理带来压力，并迫使企业采取其他筹资策略，而这可能会破坏现有的供应商关係。

从製造业的角度来看，关税导致的成本变化将促使企业重新评估生产布局。企业可能会加速回流和近岸外包趋势，以保护关键业务免受贸易波动的影响。同时，拥有全球化供应链的企业可能会重新分配生产环节，以减轻关税的影响，将细胞株开发和发酵等上游流程转移到不同的司法管辖区，同时保留製剂和灌装等下游流程，使其在监管和物流方面仍具有优势。

关税也会影响研发合作和跨境伙伴关係。合作研究通常涉及生物样本、设备和资料基础设施的转移。贸易摩擦加剧可能会增加合规负担，并增加材料转让协议的行政管理费用。对于从事国际许可和联合开发的公司而言，关税可能会使成本建模复杂化，并改变谈判的经济效益。同时，对于学术机构和规模较小的生物技术合作伙伴而言，行政负担可能会减缓转化势头。

重要的是，关税会影响商业性考量，但不会改变治疗的价值。付款人和卫生系统可能面临更高的进口疗法采购成本，这促使人们专注于筹资策略、处方集安排谈判和本地能力建设。然而，在许多司法管辖区，诸如医疗用品关税豁免和关键投入品的定向减免等缓解机制可能会抵消部分影响。因此，循证应对措施需要对受影响的关税细目、供应链节点和潜在的政策缓解措施进行细緻的梳理，并结合以供应连续性和患者可及性为优先的情景规划。

整合细分洞察，将治疗方式、治疗领域、给药途径、剂型和最终用户联繫起来，以优先考虑开发和商业投资

有效的蛋白质疗法細項分析必须整合给药方式、治疗领域、给药途径、剂型和最终用户动态，以揭示科学研究机会与商业性可行性之间的契合度。具体而言，胞浆素原激活剂和尿酸酶等酶可用于治疗急性和代谢性疾病，因此对酶学和製剂有独特的需求。同时，细胞激素融合蛋白和Fc融合蛋白等融合蛋白可延长半衰期并靶向受体，从而改变给药顺序和给药环境。激素细分为生长激素、胰岛素和甲状腺激素。随着类似物改善药物动力学，精准的给药技术和依从性支持装置的需求持续成长。干扰素（包括α、β和γ）仍然适用于利基免疫调节适应症，其中给药方案和耐受性是临床应用的关键驱动因素。单株抗体（包括嵌合体、全人抗体、人源化抗体和鼠抗体）在肿瘤学和免疫学领域具有特异性，但需要不同的免疫抗原性和製造控制。促红血球生成素、生长激素和胰岛素类似物等重组蛋白在慢性疾病管理中发挥核心作用，而疫苗（包括结合疫苗、不活化疫苗、减毒疫苗和次单元疫苗）需要强大的低温运输和人群层面的配送策略。

治疗领域的细分凸显了研发和商业化需求的差异。专注于糖尿病和生长迟缓的内分泌学计画优先考虑长期依从性、设备整合和持续安全监测。针对自体免疫疾病和发炎性疾病的免疫学产品组合必须在疗效与长期安全监测以及联合治疗潜力之间取得平衡。无论是细菌或病毒引起的传染病防治工作都需要快速的疫情应对能力和可扩展的生产能力，而针对血液系统骨髓恶性肿瘤和固体癌的肿瘤学工作流程则需要先进的生物标誌物策略和通常复杂的临床试验设计。罕见感染疾病工作，例如遗传性和溶小体贮积症，通常涉及的人群较少，每位患者的治疗强度较高，并且需要定制的临床终点，这对传统的报销模式提出了挑战。

依给药途径和剂型细分，进一步完善了策略选择。同时，肠外给药（肌肉注射、静脉注射和皮下注射）仍是许多复杂分子的主要给药方式，需要不同的设备、低温运输和给药训练。自动注射器、药筒、液体和冷冻干燥製剂、笔式註射器和预填充式注射器等剂型会影响患者的依从性、稳定性和供应链的复杂性。终端使用者细分——门诊手术中心、诊所（社区和专科）、居家医疗机构、医院（私立和公立）以及研究机构——塑造了分销管道，并为整个医疗保健领域的相关人员参与策略提供了资讯。

它还确定了与给药途径、剂型物流和最终用户能力相关的操作限制。

蛋白质疗法的区域策略影响受到全球主要地区不同的法律规范、製造能力和付款人动态的影响

由于法律规范、生产能力、支付系统和医疗服务模式的差异，区域动态显着影响蛋白质疗法的策略决策。在美洲，监管管道和成熟的报销框架支持先进的商业化策略，而集中的生产和临床研究中心则为后期开发提供了强大的基础设施。这种环境促进了激烈的竞争和高价值疗法的快速应用，同时也提高了对比较疗效和长期疗效数据的期望。

欧洲、中东和非洲地区监管和支付方格局的差异，决定了市场进入方式的差异。虽然欧洲药品法规的协调有利于广泛地区申报，但各国医疗技术评估流程和采购机制的差异，使得弹性价格设定和进入策略成为必要。在中东和非洲部分地区，增加对本地製造和产能建设的投资，为区域合作和受託製造提供了机会，但物流和低温运输限制仍然是许多地区的关键考虑因素。

亚太地区既有拥有先进研发生态系统的成熟市场，也有医疗基础设施快速发展的新兴市场，两者活力四射。该地区一些国家正在扩大生物製造产能并简化监管管道以吸引投资，而其他国家则优先考虑本地区特有的临床证据和技术转移。因此，亚太地区的打入市场策略必须在集中的区域性项目与各国在监管合规、分销和付款人谈判方面的具体调整之间取得平衡。在所有地区，跨境合作、製造韧性以及与当地卫生优先事项的契合度将决定新型蛋白质疗法的采用速度和规模。

决定竞争优势的关键公司层级策略行动，从平台差异化到製造管理，再到更广泛的合作模式

蛋白质疗法的竞争动态体现在大型综合性生物製药公司、专业化的中型市场公司和创新生物技术新兴企业的混合竞争中，每家公司在价值链上都拥有独特的能力。大型综合公司通常结合了深厚的产品线、全球製造网路和广泛的商业基础设施，使其能够执行复杂的开发专案并管理全球产品发布。中型市场公司通常专注于特定的治疗模式或治疗领域，利用在单株抗体工程或酵素替代技术等领域的专业知识来创造差异化的临床资产。新兴企业透过新颖的平台、精准的生技药品和快速的概念验证执行来贡献颠覆性创新，通常会引发与大型公司的合作或收购活动。

共同开发契约、授权协议和製造外包关係使公司能够利用互补能力，而无需重复资本支出。策略联盟也能透过将临床和监管专业知识与本地商业化管道结合，促进公司进入新的地区。同时，投资于表达系统、製程开发和灌装等垂直整合能力的公司可以更好地控制关键品质属性和供应连续性，从而在市场竞争减弱的时期获得竞争优势。

知识产权和平台差异化仍然是关键的差异化因素。专有表达技术、独特的Fc工程方法以及受保护的製剂化学成分，使公司即使在初步核准后也能保持治疗差异化。同时，对数据生成的日益重视，包括真实世界证据和长期安全性队列研究，正在塑造上市后的定位和付款人谈判。将科学新颖性与切实可行的商业化计划和弹性製造相结合的组织，最有可能从蛋白质治疗创新中获得持久价值。

为领导者提供可行的策略建议，以建立平台优势、增强供应弹性、使证据与付款人需求保持一致并实施自适应商业化模式

产业领导者应采取多维度策略，同时兼顾科学差异化、营运韧性、监管敏捷性和商业性准备。首先，优先考虑能够降低差异性并实用化上市时间的平台级投资，例如先进的表达系统、可扩展的纯化技术以及关键品质属性的稳健分析。这些投资将在效率和产品品质方面创造可持续的优势，并支持灵活应对供应中断和政策变化。

其次，我们正在透过双重采购、关键投入的策略性盘点以及能够快速扩张产能的伙伴关係关係来增强供应链的韧性。在关税影响或贸易不确定性显着的情况下，我们正在评估近岸外包和区域製造中心作为策略性缓解方案，并进行有针对性的成本效益分析，其中纳入监管时限和劳动力可用性。第三，我们正在将卫生经济学、结果研究和真实世界证据收集整合到关键计划和核准后计划中，从而使我们的临床开发和证据生成策略在专案生命週期的早期就与付款人的要求保持一致。这种协调加快了报销时间，并支持以金额为准的合约谈判。

第四，我们将采用模组化商业化方法，以反映区域监管和医疗服务交付的差异性，同时维持对核心智慧财产权和临床数据的集中控制。上市模式将根据医院、诊所、居家医疗机构和门诊手术中心之间的差异进行定制，确保设备和剂型的选择能够支持实际的给药环境。我们也将优先考虑管治、资料共用和明确的製造责任，以避免下游整合风险。这些行动将有助于将技术潜力转化为可持续的临床和商业性成果。

我们透明的三管齐下的调查方法结合了相关人员访谈、监管机构研究、技术文献和主题综合，以提供可行的结论

本报告的研究结果源自于结构化的调查方法，该方法结合了原始研究和二手资料，并进行了严格的综合分析，以确保可靠的结果。原始研究包括对生物製药开发、生产、监管事务和商业运营的高级相关人员的访谈，以及与医院和居家医疗机构的临床专家和采购相关人员的咨询。这些对话提供了关于实际限制、决策驱动因素以及现实世界应用障碍的见解，而这些往往无法透过纯粹的文献综述来理解。

二次研究包括同行评审文献、监管指南文件、临床试验登记、生产和器械技术标准以及上市公司文件。二次研究用于检验技术声明、记录过往先例并识别已发表证据的差距。资料整合将定性访谈的主题分析与交叉检验的文献证据相结合，以得出可靠的结论并揭示对相关人员具有重大意义的影响。

在整个过程中，我们强调三角测量和透明度。我们记录了关键假设，在内部咨询了资讯来源，并透过后续行动协调了不同的观点。随着证据的出现和新兴市场政策发展的不断变化，我们认识到其局限性，并将建议重点放在监管和市场情景之外的韧性行动上。

结论性综合报告强调，科学创新、製造弹性和实证商业化的整合是蛋白质疗法持续产生影响的途径

蛋白质疗法正处于关键的十字路口，科学创新与复杂的营运和政策现实交织在一起。工程、交付和製造方面的进步正在拓展治疗潜力，而监管调整和付款方成熟度的提升正在重新调整成功商业化的要求。能够将平台级科学与供应链弹性、与报销需求相符的证据生成以及自适应的地理战略相结合的组织，将最有可能实现患者效益和可持续的业务绩效。

未来最成功的公司将把卓越的技术与务实的执行力相结合：减少差异性，优先考虑支持规模化的投资，开发加速获取互补能力的伙伴关係模式，并设计反映本地医疗服务提供和付款人期望的商业化计划。透过保持策略灵活性并专注于循证决策，领导者能够将蛋白质疗法固有的机会转化为持续的临床和经济效益。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 透过位点特异性有效载荷连接开发针对肿瘤特异性标记物的抗体-药物偶联物
  • 用于快速预防免疫应用的mRNA编码单株抗体的出现
  • 整合人工智慧驱动的蛋白质工程，加速生技药品研发中的先导药物最适化
  • 扩大高浓度抗体製剂皮下给药用于治疗慢性疾病
  • 采用连续生产技术，实现经济高效的治疗性蛋白质的大规模生产
  • 基因编辑细胞疗法获监管部门核准，为罕见疾病提供个人化蛋白质治疗
  • 基于蛋白质体学的生物标记引导治疗的兴起改善了自体免疫疾病的患者分层

第六章 2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 蛋白质治疗市场（依治疗方式）

  • 酵素
    • 胞浆素原原激活剂
    • 尿酸酶
  • 融合蛋白
    • 细胞激素融合
    • Fc融合
  • 荷尔蒙
    • 生长激素
    • 胰岛素
    • 甲状腺激素
  • 干扰素
    • α干扰素
    • β型干扰素
    • 干扰素γ
  • 单株抗体
    • 嵌合体
    • 完全人类
    • 人性化
    • 老鼠
  • 重组蛋白
    • 促红血球生成素
    • 生长激素
    • 胰岛素类似物
  • 疫苗
    • 共轭
    • 惰性
    • 活病毒疫苗
    • 次单元

9. 蛋白质治疗市场（依治疗领域）

  • 内分泌学
    • 糖尿病
    • 生长迟缓
  • 免疫学
    • 自体免疫疾病
    • 发炎性疾病
  • 感染疾病
    • 细菌感染疾病
    • 病毒感染
  • 肿瘤学
    • 造血系统恶性肿瘤
      • 白血病
      • 淋巴瘤
    • 固态肿瘤
      • 乳癌
      • 大肠直肠癌
      • 肺癌
  • 罕见疾病
    • 遗传性疾病
    • 溶小体贮积症

第 10 章蛋白质治疗市场（依给药途径）

  • 肠外注射
    • 鼻腔
    • 口服
    • 经皮
  • 注射
    • 肌肉注射
    • 静脉
    • 皮下

第 11 章：蛋白质治疗市场（依剂型划分）

  • 自动注射器
  • 墨水匣
  • 液体
  • 冷冻干燥
  • 笔型注射器
  • 预填充式注射器

第 12 章：蛋白质治疗市场（以最终用户划分）

  • 门诊手术中心
  • 诊所
    • 社区诊所
    • 专科诊所
  • 居家医疗
  • 医院
    • 私立医院
    • 公立医院
  • 研究所

第 13 章：蛋白质治疗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章蛋白质治疗市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。按国家/地区分類的蛋白质治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • F. Hoffmann-La Roche Ltd
    • AbbVie Inc.
    • Merck & Co., Inc.
    • Novo Nordisk A/S
    • Amgen Inc.
    • Johnson & Johnson
    • Bristol-Myers Squibb Company
    • Sanofi SA
    • Eli Lilly and Company
    • Pfizer Inc.
Product Code: MRR-035AB9C0DA41

The Protein Therapeutics Market is projected to grow by USD 158.57 billion at a CAGR of 8.13% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 84.80 billion
Estimated Year [2025] USD 91.79 billion
Forecast Year [2032] USD 158.57 billion
CAGR (%) 8.13%

An authoritative introduction framing protein therapeutics as a convergent field where scientific innovation, supply resilience, and commercial strategy determine patient impact and industry trajectories

Protein therapeutics have evolved from niche biologic interventions to a central pillar of modern medicine, advancing patient care across multiple therapeutic areas through improved specificity, potency, and personalization. This introduction synthesizes the contemporary landscape by integrating scientific innovation with operational realities, and by aligning stakeholder expectations across research, manufacturing, clinical development, and commercialization. It frames the sectors of enzymes, fusion proteins, hormones, interferons, monoclonal antibodies, recombinant proteins, and vaccines as interconnected modalities that together form a complex ecosystem of discovery and delivery.

As modalities diversify, so do the pathways to market and the strategic choices facing organizations. Innovations in protein engineering and formulation are reducing immunogenicity and enhancing stability, while delivery innovations expand viable routes of administration beyond traditional parenteral approaches. Concurrently, evolving payer dynamics and regulatory scrutiny are shifting the calculus of clinical development and lifecycle management, intensifying the need for integrated evidence generation strategies. This introduction establishes the analytical lens used throughout the report: an emphasis on translational impact, supply-chain resilience, and commercial readiness that collectively enable stakeholders to navigate scientific complexity and policy shifts with clarity and purpose.

Throughout the following sections, readers will find an emphasis on actionable insight rather than abstract trend spotting. The objective is to provide leaders with a pragmatic foundation to align R&D portfolios, manufacturing investments, and market entry strategies with the scientific and systemic forces shaping protein therapeutics today.

How recent technological advances, regulatory evolution, and shifting payer expectations are converging to fundamentally reshape discovery, development, and commercial strategies in protein therapeutics

The landscape of protein therapeutics is undergoing transformative shifts driven by technological breakthroughs, regulatory modernization, and changing stakeholder expectations. Advances in molecular engineering, such as precision glycoengineering and Fc region optimization, have extended functional lifetimes and targeted tissue distribution for monoclonal antibodies and fusion proteins. At the same time, next-generation recombinant expression systems and cell-free manufacturing platforms are reducing production variability and shortening development timelines, enabling more reproducible supply for complex biologics.

Parallel to these technological evolutions, clinical paradigms are shifting toward combination regimens and biomarker-driven patient selection. Oncology and immunology programs increasingly adopt companion diagnostics to refine responder populations, while rare disease initiatives leverage improved understanding of genetic etiology to accelerate development of targeted protein replacements and enzyme therapies. Delivery modalities are advancing in step: improvements in formulation science and device integration are making subcutaneous and intramuscular administrations viable for larger and more complex molecules, while non-parenteral approaches such as nasal and transdermal delivery are moving from conceptual demonstration toward early clinical application for selected indications.

Furthermore, regulatory frameworks are adapting to the unique characteristics of protein therapeutics. Agencies are refining guidance on biosimilarity, interchangeability, and real-world evidence acceptance, which creates both opportunities and complexities for developers. Regulatory flexibility around accelerated pathways and adaptive trial designs is enabling faster access to transformative therapies, but it also raises the bar for post-approval safety monitoring and manufacturing control. Finally, payer dynamics and value-based contracting are reshaping commercial strategies, prompting sponsors to align evidence generation with long-term outcomes and to consider risk-sharing models that tie reimbursement to demonstrated clinical benefit. Together, these forces are redefining how organizations prioritize assets, structure partnerships, and invest in capabilities that span discovery through delivery.

Comprehensive analysis of the cascading operational, supply-chain, and partnership effects stemming from United States tariff measures slated for 2025 within the protein therapeutics value chain

The cumulative impact of United States tariffs announced for 2025 must be analyzed through multiple operational and strategic lenses to understand their implications for protein therapeutics. Trade measures that affect raw materials, laboratory consumables, equipment, and intermediary goods increase costs and complicate procurement workflows, particularly for biologics manufacturing which relies on specialized inputs and high-quality reagents. In practice, tariffs can lengthen lead times for critical supplies, create inventory management pressures, and necessitate alternative sourcing strategies that can disrupt established supplier relationships.

From a manufacturing perspective, tariff-driven cost shifts incentivize re-evaluation of production footprints. Organizations may accelerate trends toward reshoring or nearshoring to insulate critical operations from trade volatility, but doing so requires substantial capital investment and regulatory alignment. In parallel, firms with globalized supply chains may redistribute production stages to mitigate tariff exposure, shifting upstream activities such as cell line development and fermentation to different jurisdictions while maintaining downstream formulation and fill-finish where regulatory and logistical advantages persist.

Tariffs also affect R&D collaboration and cross-border partnerships. Collaborative research often involves the transfer of biological samples, instrumentation, and data infrastructure; increased trade friction can raise compliance burdens and add administrative overhead to material transfer agreements. For companies engaged in international licensing or co-development, tariffs complicate cost modeling and may alter negotiated economics, while for academic and small biotech partners, the administrative workload can slow translational momentum.

Crucially, tariffs influence commercial considerations without changing therapeutic value. Payers and health systems may face higher acquisition costs for imported therapies, prompting intensified focus on procurement strategies, formulary placement negotiations, and local capacity development. Yet, in many jurisdictions, mitigating mechanisms such as tariff exemptions for medical goods or targeted relief for critical inputs may offset portions of the impact. Therefore, an evidence-based response requires granular mapping of affected tariff lines, supply-chain nodes, and potential policy mitigations, combined with scenario planning that prioritizes continuity of supply and patient access.

Integrated segmentation insight that connects modality, therapeutic area, administration route, dosage form, and end-user considerations to prioritize development and commercial investment

Effective segmentation analysis in protein therapeutics must integrate modality, therapeutic area, route of administration, dosage form, and end-user dynamics to reveal where scientific opportunity aligns with commercial viability. Modality-level distinctions are meaningful: enzymes, including plasminogen activators and uricase, address acute and metabolic disorders with specific enzymology and formulation needs, while fusion proteins-spanning cytokine fusion and Fc fusion constructs-offer tailored half-life extension and receptor targeting capabilities that alter dosing cadence and administration settings. Hormones, subdivided into growth hormone, insulin, and thyroid hormones, continue to demand precise delivery technologies and adherence-supporting devices, particularly as analogues enable refined pharmacokinetics. Interferons, in their alpha, beta, and gamma forms, remain relevant in niche immunomodulatory indications where dosing schedule and tolerability drive clinical adoption. Monoclonal antibodies, whether chimeric, fully human, humanized, or murine, deliver specificity across oncology and immunology but require distinct immunogenicity and manufacturing controls. Recombinant proteins such as erythropoietin, growth hormones, and insulin analogues maintain a central role in chronic disease management, and vaccines-across conjugate, inactivated, live attenuated, and subunit types-demand robust cold chain logistics and population-level delivery strategies.

Therapeutic area segmentation highlights differential R&D and commercialization demands. Endocrinology programs focused on diabetes and growth disorders prioritize long-term adherence, device integration, and sustained safety surveillance. Immunology portfolios targeting autoimmune and inflammatory disorders must balance efficacy with chronic safety monitoring and combination therapy potential. Infectious disease efforts, whether addressing bacterial or viral pathogens, require rapid response capabilities and scalable manufacturing for outbreaks, while oncology workstreams in hematological malignancies and solid tumors demand sophisticated biomarker strategies and often complex clinical trial designs. Rare disease initiatives for genetic disorders and lysosomal storage disorders typically involve smaller populations, high per-patient treatment intensities, and bespoke clinical endpoints that challenge conventional reimbursement models.

Route-of-administration and dosage-form segmentation further refine strategic choices. Non-parenteral options-nasal, oral, transdermal-offer patient-centric benefits but face formidable formulation and absorption barriers for large proteins, whereas parenteral routes-intramuscular, intravenous, subcutaneous-remain the mainstay for many complex molecules and dictate different device, cold-chain, and administration training needs. Dosage forms such as auto-injectors, cartridges, liquid and lyophilized presentations, pen injectors, and pre-filled syringes influence patient adherence, stability, and supply-chain complexity. End-user segmentation across ambulatory surgical centers, clinics (community and specialty), homecare settings, hospitals (private and public), and research institutes shapes distribution channels and informs engagement strategies for stakeholders across the healthcare continuum.

Taken together, this layered segmentation approach clarifies where investment in formulation innovation, device co-development, or targeted clinical evidence will yield the greatest impact, while also identifying operational constraints tied to administration route, dosage form logistics, and end-user capabilities.

Regional strategic implications for protein therapeutics shaped by divergent regulatory frameworks, manufacturing capacity, and payer dynamics across major global regions

Regional dynamics materially influence strategic decisions for protein therapeutics due to differences in regulatory frameworks, manufacturing capacity, payer systems, and healthcare delivery models. In the Americas, regulatory pathways and established reimbursement frameworks support advanced commercialization strategies, while concentrated centers of manufacturing and clinical research provide robust infrastructure for late-stage development. This environment fosters intense competition and rapid adoption for high-value therapies, but it also elevates expectations around comparative effectiveness and long-term outcome data.

Europe, Middle East & Africa presents heterogeneous regulatory and payer landscapes that demand tailored market-entry approaches. European regulatory harmonization offers advantages for pan-regional submissions, yet variations in national HTA processes and procurement mechanisms require flexible pricing and access strategies. In parts of the Middle East and Africa, investments in local manufacturing and capacity building are increasing, offering opportunities for regional partnerships and contract manufacturing initiatives, though logistics and cold-chain constraints remain significant considerations in many areas.

Asia-Pacific features a dynamic mix of mature markets with advanced R&D ecosystems and emerging markets with rapidly evolving healthcare infrastructure. Several countries in the region are expanding biomanufacturing capabilities and streamlining regulatory pathways to attract investment, while others prioritize localized clinical evidence and technology transfer. Market entry strategies in Asia-Pacific must therefore balance centralized regional programs with country-specific adaptations for regulatory compliance, distribution, and payer negotiation. Across all regions, cross-border collaboration, manufacturing resilience, and alignment with local health priorities will determine the pace and scale of adoption for novel protein therapeutics.

Key company-level strategic behaviors that determine competitive advantage from platform differentiation to manufacturing control and far-reaching partnership models

Competitive dynamics in protein therapeutics are characterized by a mix of large integrated biopharmaceutical firms, specialized mid-size players, and innovative biotechnology startups, each contributing distinct capabilities to the value chain. Large integrated companies typically combine deep pipelines, global manufacturing networks, and extensive commercial infrastructure, enabling them to execute complex development programs and manage global launches. Mid-size firms often specialize in particular modalities or therapeutic niches, leveraging focused expertise in areas such as monoclonal antibody engineering or enzyme replacement technologies to create differentiated clinical assets. Startups contribute disruptive innovation through novel platforms, precision biologics, and rapid proof-of-concept execution, frequently catalyzing partnerships or acquisition activity with larger organizations.

Partnership models are increasingly central to competitiveness: co-development agreements, licensing arrangements, and contract manufacturing relationships allow organizations to access complementary capabilities without duplicative capital outlays. Strategic alliances also facilitate entry into new geographies by pairing clinical or regulatory expertise with local commercialization channels. Meanwhile, companies that invest in vertically integrated capabilities around expression systems, process development, and fill-finish demonstrate greater control over critical quality attributes and supply continuity, which can become a competitive advantage during periods of market stress.

Intellectual property and platform differentiation remain key differentiators. Proprietary expression technologies, unique Fc-engineering approaches, and protected formulation chemistries enable firms to sustain therapeutic differentiation beyond initial approval. At the same time, an increased emphasis on data generation - including real-world evidence and long-term safety cohorts - is shaping post-market positioning and payer negotiations. Organizations that align scientific novelty with pragmatic commercialization planning and resilient manufacturing will be best positioned to capture durable value from protein therapeutics innovations.

Actionable strategic recommendations for leaders to build platform advantages, fortify supply resilience, align evidence with payer needs, and execute adaptive commercialization models

Industry leaders should adopt a multi-dimensional strategy that simultaneously addresses scientific differentiation, operational resilience, regulatory agility, and commercial readiness. First, prioritize platform-level investments that reduce variability and accelerate translation, such as advanced expression systems, scalable purification technologies, and robust analytics for critical quality attributes. These investments create durable advantages in both efficiency and product quality, and they support flexible responses to supply interruptions or policy shifts.

Second, strengthen supply-chain resilience through dual sourcing, strategic inventory policies for critical inputs, and partnerships that enable rapid capacity scaling. Where tariff exposure or trade uncertainty is material, evaluate nearshoring and regional manufacturing hubs as strategic mitigations, and conduct targeted cost-benefit analyses that incorporate regulatory timeframes and workforce availability. Third, align clinical development and evidence-generation strategies with payer requirements early in the program lifecycle by integrating health economics, outcomes research, and real-world evidence collection into pivotal and post-approval plans. This alignment reduces time to reimbursement and supports value-based contracting discussions.

Fourth, embrace modular commercialization approaches that reflect regional regulatory and healthcare delivery heterogeneity while preserving centralized control of core intellectual property and clinical data. Tailor market-entry models to account for differences across hospitals, clinics, homecare settings, and ambulatory surgical centers, and ensure that device and dosage-form choices support real-world administration environments. Finally, cultivate flexible partnership models that combine the innovation speed of smaller developers with the execution capabilities of larger firms, and prioritize clarity in governance, data-sharing, and manufacturing responsibilities to prevent downstream integration risks. Together, these actions will enable leaders to convert technological promise into sustainable clinical and commercial outcomes.

Transparent and triangulated research methodology combining stakeholder interviews, regulatory review, technical literature, and thematic synthesis to underpin actionable conclusions

This report's findings derive from a structured research methodology that combines primary qualitative engagement, targeted secondary research, and rigorous synthesis to ensure actionable credibility. Primary research included interviews with senior stakeholders across biopharmaceutical development, manufacturing, regulatory affairs, and commercial operations, as well as consultations with clinical experts and procurement leaders in hospital and homecare settings. These conversations provided insight into practical constraints, decision-making drivers, and real-world adoption barriers that are often invisible to pure literature reviews.

Secondary research encompassed peer-reviewed literature, regulatory guidance documents, clinical trial registries, manufacturing and device technical standards, and publicly disclosed company materials. The secondary phase was used to validate technical assertions, document historical precedent, and identify published evidence gaps. Data synthesis integrated thematic analysis from qualitative interviews with cross-validated documentary evidence to generate robust conclusions and to surface high-impact implications for stakeholders.

Throughout the process, emphasis was placed on triangulation and transparency: key assumptions are documented, sources are referenced internally, and divergent perspectives are reconciled through follow-up engagement. Limitations are acknowledged where evidence is emergent or where policy developments remain fluid, and recommendations focus on actions that are resilient across plausible regulatory and market scenarios.

Concluding synthesis that emphasizes integration of scientific innovation, manufacturing resilience, and evidence-driven commercialization as the pathway to sustained impact in protein therapeutics

Protein therapeutics stand at a pivotal juncture where scientific innovation meets complex operational and policy realities. Advances in engineering, delivery, and manufacturing are expanding therapeutic possibilities, while regulatory adaptation and payer sophistication are recalibrating the requirements for successful commercialization. Organizations that integrate platform-level science with supply-chain resilience, evidence-generation aligned to reimbursement needs, and adaptive regional strategies will be best positioned to realize both patient impact and sustainable business performance.

Looking forward, the most successful actors will combine technical excellence with pragmatic execution: they will prioritize investments that reduce variability and support scale, build partnership models that accelerate access to complementary capabilities, and design commercialization plans that reflect local healthcare delivery and payer expectations. By maintaining strategic flexibility and focusing on evidence-driven decision making, leaders can convert the opportunities inherent in protein therapeutics into durable clinical and economic outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growth of antibody-drug conjugates targeting tumor-specific markers with site-specific payload conjugation
  • 5.2. Emergence of mRNA-encoded monoclonal antibodies for rapid preventive immunization applications
  • 5.3. Integration of AI-driven protein engineering to accelerate lead optimization in biologics discovery
  • 5.4. Expansion of subcutaneous delivery formats for high-concentration antibody formulations in chronic diseases
  • 5.5. Adoption of continuous manufacturing technologies for cost-effective large-scale therapeutic protein production
  • 5.6. Regulatory approval of gene-edited cell therapies offering personalized protein-based treatments for rare diseases
  • 5.7. Rise of proteomics-informed biomarker-guided therapies improving patient stratification in autoimmune disorders

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Protein Therapeutics Market, by Modality

  • 8.1. Enzymes
    • 8.1.1. Plasminogen Activators
    • 8.1.2. Uricase
  • 8.2. Fusion Proteins
    • 8.2.1. Cytokine Fusion
    • 8.2.2. Fc Fusion
  • 8.3. Hormones
    • 8.3.1. Growth Hormone
    • 8.3.2. Insulin
    • 8.3.3. Thyroid Hormones
  • 8.4. Interferons
    • 8.4.1. Interferon Alpha
    • 8.4.2. Interferon Beta
    • 8.4.3. Interferon Gamma
  • 8.5. Monoclonal Antibodies
    • 8.5.1. Chimeric
    • 8.5.2. Fully Human
    • 8.5.3. Humanized
    • 8.5.4. Murine
  • 8.6. Recombinant Proteins
    • 8.6.1. Erythropoietin
    • 8.6.2. Growth Hormones
    • 8.6.3. Insulin Analogues
  • 8.7. Vaccines
    • 8.7.1. Conjugate
    • 8.7.2. Inactivated
    • 8.7.3. Live Attenuated
    • 8.7.4. Subunit

9. Protein Therapeutics Market, by Therapeutic Area

  • 9.1. Endocrinology
    • 9.1.1. Diabetes
    • 9.1.2. Growth Disorders
  • 9.2. Immunology
    • 9.2.1. Autoimmune Disorders
    • 9.2.2. Inflammatory Disorders
  • 9.3. Infectious Diseases
    • 9.3.1. Bacterial Infections
    • 9.3.2. Viral Infections
  • 9.4. Oncology
    • 9.4.1. Hematological Malignancies
      • 9.4.1.1. Leukemia
      • 9.4.1.2. Lymphoma
    • 9.4.2. Solid Tumors
      • 9.4.2.1. Breast Cancer
      • 9.4.2.2. Colorectal Cancer
      • 9.4.2.3. Lung Cancer
  • 9.5. Rare Diseases
    • 9.5.1. Genetic Disorders
    • 9.5.2. Lysosomal Storage Disorders

10. Protein Therapeutics Market, by Route Of Administration

  • 10.1. Non Parenteral
    • 10.1.1. Nasal
    • 10.1.2. Oral
    • 10.1.3. Transdermal
  • 10.2. Parenteral
    • 10.2.1. Intramuscular
    • 10.2.2. Intravenous
    • 10.2.3. Subcutaneous

11. Protein Therapeutics Market, by Dosage Form

  • 11.1. Auto Injectors
  • 11.2. Cartridges
  • 11.3. Liquid
  • 11.4. Lyophilized
  • 11.5. Pen Injectors
  • 11.6. Pre Filled Syringes

12. Protein Therapeutics Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
    • 12.2.1. Community Clinics
    • 12.2.2. Specialty Clinics
  • 12.3. Homecare
  • 12.4. Hospitals
    • 12.4.1. Private Hospitals
    • 12.4.2. Public Hospitals
  • 12.5. Research Institutes

13. Protein Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Protein Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Protein Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. AbbVie Inc.
    • 16.3.3. Merck & Co., Inc.
    • 16.3.4. Novo Nordisk A/S
    • 16.3.5. Amgen Inc.
    • 16.3.6. Johnson & Johnson
    • 16.3.7. Bristol-Myers Squibb Company
    • 16.3.8. Sanofi S.A.
    • 16.3.9. Eli Lilly and Company
    • 16.3.10. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MODALITY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS PROTEIN THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. PROTEIN THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. PROTEIN THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PROTEIN THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ENZYMES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ENZYMES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMINOGEN ACTIVATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMINOGEN ACTIVATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMINOGEN ACTIVATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMINOGEN ACTIVATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMINOGEN ACTIVATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMINOGEN ACTIVATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY URICASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY URICASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY URICASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY URICASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY URICASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY URICASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY CYTOKINE FUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY CYTOKINE FUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY CYTOKINE FUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY CYTOKINE FUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY CYTOKINE FUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY CYTOKINE FUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FC FUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FC FUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FC FUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FC FUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FC FUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FC FUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HORMONES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HORMONES, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HORMONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HORMONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HORMONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HORMONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROWTH HORMONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROWTH HORMONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROWTH HORMONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROWTH HORMONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROWTH HORMONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROWTH HORMONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INSULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INSULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INSULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY THYROID HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY THYROID HORMONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY THYROID HORMONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY THYROID HORMONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY THYROID HORMONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY THYROID HORMONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERONS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERONS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERON ALPHA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERON ALPHA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERON ALPHA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERON ALPHA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERON ALPHA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERON ALPHA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERON BETA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERON BETA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERON BETA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERON BETA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERON BETA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERON BETA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERON GAMMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERON GAMMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERON GAMMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERON GAMMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERON GAMMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERON GAMMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FULLY HUMAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MURINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MURINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MURINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MURINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MURINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MURINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ERYTHROPOIETIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ERYTHROPOIETIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ERYTHROPOIETIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ERYTHROPOIETIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROWTH HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROWTH HORMONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROWTH HORMONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROWTH HORMONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROWTH HORMONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROWTH HORMONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INSULIN ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INSULIN ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INSULIN ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INSULIN ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INSULIN ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INSULIN ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROWTH DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROWTH DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROWTH DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROWTH DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROWTH DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROWTH DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INFLAMMATORY DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INFLAMMATORY DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INFLAMMATORY DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INFLAMMATORY DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INFLAMMATORY DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INFLAMMATORY DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2024 (US